ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide
ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide |
|
https://doi.org/10.18632/oncotarget.28090
Lara H. El Touny,
Curtis Hose,
John Connelly,
Erik Harris,
Anne Monks,
Angie B. Dull,
Deborah F. Wilsker,
Melinda G. Hollingshead,
Michelle Gottholm-Ahalt,
Sergio Y. Alcoser,
Michael E. Mullendore,
Ralph E. Parchment,
James H. Doroshow,
Beverly A. Teicher,
and Annamaria Rapisarda
|
| 2114-2130 |
Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab |
|
https://doi.org/10.18632/oncotarget.28086
Ilyas Sahin,
Andrew George,
Shengliang Zhang,
Kelsey E. Huntington,
Zehra Ordulu,
Lanlan Zhou,
and Wafik S. El-Deiry
|
| 2131-2146 |
Luminescence complementation technology for the identification of MYC:TRRAP inhibitors
Luminescence complementation technology for the identification of MYC:TRRAP inhibitors |
|
https://doi.org/10.18632/oncotarget.28078
Edmond J. Feris,
John W. Hinds,
and Michael D. Cole
|
| 2147-2157 |
TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan |
|
https://doi.org/10.18632/oncotarget.28073
Erling Håland,
Ingrid Nyhus Moen,
Elias Veidal,
Hanne Hella,
Kristine Misund,
Tobias S. Slørdahl,
and Kristian K. Starheim
|
| 2158-2168 |
The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey
The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey |
|
https://doi.org/10.18632/oncotarget.28076
Subotheni Thavaneswaran,
Mandy Ballinger,
Phyllis Butow,
Bettina Meiser,
David Goldstein,
Frank Lin,
Christine Napier,
David Thomas,
and Megan Best
|
| 2169-2176 |
Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma |
|
https://doi.org/10.18632/oncotarget.28069
Kelsey Maddison,
Moira C. Graves,
Nikola A. Bowden,
Michael Fay,
Ricardo E. Vilain,
Sam Faulkner,
and Paul A. Tooney
|
| 2177-2187 |
Trends in oligomannosylation and α1,2-mannosidase expression in human cancers
Trends in oligomannosylation and α1,2-mannosidase expression in human cancers |
|
https://doi.org/10.18632/oncotarget.28064
Sayantani Chatterjee,
Julian Ugonotti,
Ling Y. Lee,
Arun Everest-Dass,
Rebeca Kawahara,
and Morten Thaysen-Andersen
|
| 2188-2205 |
TP53 mutations determined by targeted NGS in breast cancer: a case-control study
TP53 mutations determined by targeted NGS in breast cancer: a case-control study |
|
https://doi.org/10.18632/oncotarget.28071
Angeliki Andrikopoulou,
Evangelos Terpos,
Spyridoula Chatzinikolaou,
Kleoniki Apostolidou,
Ioannis Ntanasis-Stathopoulos,
Maria Gavriatopoulou,
Meletios-Athanasios Dimopoulos,
and Flora Zagouri
|
| 2206-2214 |
Association of four genetic variants with colorectal cancer in Kazakhstan population
Association of four genetic variants with colorectal cancer in Kazakhstan population |
|
https://doi.org/10.18632/oncotarget.28070
Yevgeniya Kolesnikova,
Dmitriy Babenko,
Irina Kadyrova,
Svetlana Kolesnichenko,
Lyudmila Akhmaltdinova,
Ilya Korshukov,
Naylya Kabildina,
Valentina Sirota,
Vera Zhumaliyeva,
Dana Taizhanova,
Dmitriy Vazenmiller,
and Anar Turmukhambetova
|
| 2215-2222 |
Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?
Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy? |
|
https://doi.org/10.18632/oncotarget.27987
Yao Yu,
Kaveh Zakeri,
and Nancy Lee
|
| 2223-2226 |
Neddylation and anti-tumor immunity
Neddylation and anti-tumor immunity |
|
https://doi.org/10.18632/oncotarget.28019
Xiaoguang Wang,
Scott Best,
and Alexey V. Danilov
|
| 2227-2230 |
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201 |
|
https://doi.org/10.18632/oncotarget.28012
Joshua E. Allen,
C. Leah B. Kline,
Varun V. Prabhu,
Jessica Wagner,
Jo Ishizawa,
Neel Madhukar,
Avital Lev,
Marie Baumeister,
Lanlan Zhou,
Amriti Lulla,
Martin Stogniew,
Lee Schalop,
Cyril Benes,
Howard L. Kaufman,
Richard S. Pottorf,
B. Rao Nallaganchu,
Gary L. Olson,
Fahd Al-Mulla,
Madeleine Duvic,
Gen Sheng Wu,
David T. Dicker,
Mala K. Talekar,
Bora Lim,
Olivier Elemento,
Wolfgang Oster,
Joseph Bertino,
Keith Flaherty,
Michael L. Wang,
Gautam Borthakur,
Michael Andreeff,
Mark Stein,
and Wafik S. El-Deiry
|
| 2231-2231 |
Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer |
|
https://doi.org/10.18632/oncotarget.28096
Takahito Sugase,
Tsuyoshi Takahashi,
Satoshi Serada,
Minoru Fujimoto,
Tomoharu Ohkawara,
Kosuke Hiramatsu,
Masahiro Koh,
Yurina Saito,
Koji Tanaka,
Yasuhiro Miyazaki,
Tomoki Makino,
Yukinori Kurokawa,
Makoto Yamasaki,
Kiyokazu Nakajima,
Kazuhiro Hanazaki,
Masaki Mori,
Yuichiro Doki,
and Tetsuji Naka
|
| 2232-2233 |
